New research shows fat buildup disables brain’s immune defenses in Alzheimer’s. A mouse treatment cleared plaques in just one week.

Mount Sinai scientists analyzed over 12,000 brain proteins, uncovering how neuron–glia communication failures drive Alzheimer ...

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that lecanemab (Leqembi) has been approved for once every four weeks intravenous (IV) maintenance dosing for the ...

A monoclonal antibody (mAb), remternetug acts by targeting N3pG beta-amyloid, known as amyloid precursor protein ... III Alzheimer’s disease trial (NCT06709014). Buntanetap offers a unique ...

In January 2024, LEQEMBI was approved for the treatment of Alzheimer's disease (AD) in patients with mild cognitive impairment (MCI) or mild dementia stage of disease (collectively referred to as ...

We address this question through investigation of the progressive nature of neurodegeneration in both invertebrate and ...

A recent study conducted by the Icahn School of Medicine at Mount Sinai provides one of the most thorough insights to date ...

This award strongly validates our approach to Alzheimer’s disease,” said Dr. Carmela Abraham, Chief Science Officer. “With NIH support, we are one step closer to helping patients suffering from this ...

A new study led by the Icahn School of Medicine at Mount Sinai offers one of the most comprehensive views yet of how brain ...

In Alzheimer’s disease, Hameroff says, scientists don’t know whether the microtubules disintegrate and release the tau or whether the tau falls off because of a malfunction that weakens the bond. The ...

For decades, scientists believed Alzheimer’s was driven mainly by sticky protein plaques and tangles in the brain. Now Purdue researchers have revealed a hidden culprit: fat. They found that brain ...